<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736904</url>
  </required_header>
  <id_info>
    <org_study_id>wXELIRI vs FOLFIRI in CRC</org_study_id>
    <nct_id>NCT01736904</nct_id>
  </id_info>
  <brief_title>wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients</brief_title>
  <official_title>A Multicenter, Randomized Phase II Study of Weekly XELIRI Regimen Versus FOLFIRI in the Treatment of Advanced Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare weekly-XELIRI(wXELIRI) regimen versus FOLFIRI regimen in
      the treatment of advanced colorectal cancer patients. The hypothesis is the efficacy of
      wXELIRI is not less than FOLFIRI with tolerable toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of irinotecan and fluorouracil drugs regimen is frequently used in patients
      with advanced colorectal cancer. According to the previous data, higher rate of diarrhea was
      observed in the combination of irinotecan and capecitabine (XELIRI) regimen, compared to the
      combination of irinotecan and 5-fluorouracil (FOLFIRI) regimen. However, the modified weekly
      XELIRI regimen, which was investigated in our previous single armed study, show tolerate
      toxicities compared with FOLFIRI, without compromising efficacy. It is supposed that wXELIRI
      regimen is no less less than FOLFIRI regimen in efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival which is calculated from the start of treatment to disease progression or death</measure>
    <time_frame>eight weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate which includes complete response(CR) and partial response(PR) participants</measure>
    <time_frame>eight weeks</time_frame>
    <description>Objective response rate (ORR)= CR(complete response)+PR(partial response)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival which is calculated from the start to treatment to the death</measure>
    <time_frame>eight months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFIRI regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>wXELIRI regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>wXELIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>wXELIRI regimen</intervention_name>
    <description>irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days</description>
    <arm_group_label>wXELIRI regimen</arm_group_label>
    <other_name>wXELIRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
    <description>irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>FOLFIRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Second-line treatment for advanced colorectal cancer,irinotecan was not previously
             used.

          -  Age range 18-70 years old

          -  ECOG performance status 0-1

          -  Life expectancy of more than 3 months

          -  Adequate organ function

        Exclusion Criteria:

          -  Previous serious cardiac disease

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  Pregnant or lactating women

          -  chronic inflammatory bowel disease or intestinal obstruction

          -  Serious uncontrolled diseases and intercurrent infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Lin, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, PhD,MD</last_name>
    <phone>64175590-5109</phone>
    <email>fudanlijin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin Li, PhD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jin Li</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>advanced colorectal cancer</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>XELIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

